My Take on the Most Clinically Relevant New Data in Atopic Dermatitis
  • CME
  • CE

From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
Following the virtual 2020 American Academy of Dermatology and Revolutionizing Atopic Dermatitis conferences, I describe several of the most clinically relevant data on approved and investigational treatments that have the potential to improve outcomes for our patients.
Andrew F. Alexis, MD, MPH
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.5 Nursing contact hours
Released: August 10, 2020 Expiration: August 9, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Critically evaluate study results from recent trials of AD regarding treatment efficacy and safety
  • Describe how new trial data will affect/change the management of patients with AD

Acknowledgements

Provided by Clinical Care Options.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This educational activity is supported by educational grants from
AbbVie Inc.
Pfizer Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Andrew F. Alexis, MD, MPH

Professor and Chair
Department of Dermatology
Mount Sinai West and Mount Sinai Morningside
Director, Skin of Color Center
New York, New York

Andrew Alexis, MD, MPH, has disclosed that he has received contracted research support from Almirall, Bristol-Myers-Squibb, Cara, Celgene, Galderma, Leo, Menlo, Novartis, and Valeant (Bausch Health); and has served as a consultant for Beiersdorf, Bristol-Myers-Squibb, Cassiopea, Celgene, Dermavant, Foamix, Galderma, Leo, L’Oreal, Menlo, Novartis, Pfizer, Sanofi-Regeneron, Scientis, UCB, Unilever, and Valeant (Bausch Health).

Staff

Taryn O'Loughlin Gross, PhD

Editorial Contributor

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees for non-CME services from Salix Pharmaceuticals, Saluda Medical, and Shionogi, Inc.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The primary target audience for the activities includes dermatologists, immunologists, nurses, and other healthcare providers who treat patients with moderate to severe AD.

Goal

The goal of this initiative is to provide dermatologists and allergists with data on current and emerging therapies for moderate to severe AD presented at the virtual RAD 2020 and AAD 2020 conferences.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 10, 2020, through August 09, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

A review on how new and emerging data in the management of atopic dermatitis will affect clinical practice: atopic dermatitis conference coverage from CCO

Andrew F. Alexis, MD, MPH Jonathan Silverberg, MD Released: September 21, 2020

Expert-authored commentary on investigational selective JAK inhibitors in atopic dermatitis treatment from Clinical Care Options (CCO)

Jonathan Silverberg, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Released: August 12, 2020 Expired: August 11, 2021

Efficacy, safety of baricitinib in patients with moderate to severe atopic dermatitis in BREEZE-AD5: atopic dermatitis conference coverage from CCO

Released: August 11, 2020

Effect of withdrawal and retreatment with upadacitinib during an interim analysis of the 88-week phase 2b trial, from CCO

Released: July 27, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?